<code id='EC2F260D8E'></code><style id='EC2F260D8E'></style>
    • <acronym id='EC2F260D8E'></acronym>
      <center id='EC2F260D8E'><center id='EC2F260D8E'><tfoot id='EC2F260D8E'></tfoot></center><abbr id='EC2F260D8E'><dir id='EC2F260D8E'><tfoot id='EC2F260D8E'></tfoot><noframes id='EC2F260D8E'>

    • <optgroup id='EC2F260D8E'><strike id='EC2F260D8E'><sup id='EC2F260D8E'></sup></strike><code id='EC2F260D8E'></code></optgroup>
        1. <b id='EC2F260D8E'><label id='EC2F260D8E'><select id='EC2F260D8E'><dt id='EC2F260D8E'><span id='EC2F260D8E'></span></dt></select></label></b><u id='EC2F260D8E'></u>
          <i id='EC2F260D8E'><strike id='EC2F260D8E'><tt id='EC2F260D8E'><pre id='EC2F260D8E'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:12
          Mark Lennihan/AP

          Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

          The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

          advertisement

          Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          A biotech analyst on neuroscience, placebo effect, not over
          A biotech analyst on neuroscience, placebo effect, not over

          PaulMatteis(right),in2017withthen-colleaguesSeamusFernandez(farleft)GeoffreyPorges.AlexHogan/STATNEW

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          American woman, child freed after being kidnapped in Haiti last month

          0:26InthisundatedphotoprovidedbyElRoiHaiti,AlixDorsainvil,right,poseswithherhusband,SandroDorsainvil